- Home
- PAXS vs KURA Comparison
PAXS vs KURA Comparison
Compare PAXS & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$8.63
Company Overview
Basic Information| Metric | PAXS | KURA |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 721.4M | 744.0M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PAXS | KURA |
|---|---|---|
| Price | $14.47 | $8.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $26.63 |
| AVG Volume (30 Days) | 185.2K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $124.03 |
| Revenue Next Year | N/A | $28.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $13.63 | $5.41 |
| 52 Week High | $16.56 | $12.49 |
Technical Indicators
Market Signals| Indicator | PAXS | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 28.06 | 48.10 |
| Support Level | N/A | $7.99 |
| Resistance Level | $16.07 | $10.50 |
| Average True Range (ATR) | 0.30 | 0.41 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 7.41 | 45.83 |
Price Performance
Historical Comparison PAXS
KURA
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.